Silence Therapeutics (NASDAQ:SLN) Shares Down 9.3% – What’s Next?

by · The Markets Daily

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report)’s stock price fell 9.3% on Tuesday . The stock traded as low as $6.72 and last traded at $6.72. 173,968 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 235,292 shares. The stock had previously closed at $7.41.

Analyst Ratings Changes

SLN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Monday, December 9th. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Morgan Stanley reissued an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $57.20.

View Our Latest Analysis on Silence Therapeutics

Silence Therapeutics Trading Down 5.7 %

The company has a fifty day simple moving average of $9.52 and a two-hundred day simple moving average of $15.43. The company has a market cap of $189.74 million, a PE ratio of -4.04 and a beta of 1.08.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently added to or reduced their stakes in SLN. GAMMA Investing LLC increased its position in shares of Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Silence Therapeutics during the third quarter worth $56,000. Quarry LP purchased a new position in Silence Therapeutics in the second quarter valued at $114,000. Verition Fund Management LLC acquired a new stake in Silence Therapeutics in the third quarter valued at $207,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Silence Therapeutics in the third quarter valued at $318,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Further Reading